VarCov Co’s Maravai LifeSciences MRVI Stock Holding History

VarCov Co’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-161,685	Closed	-$458K	–	485
2026 Q1	$458K	Buy	+161,685	New	+$548K	0.17%	226

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

VarCov Co's MRVI Position: Q2 2026 in Review

VarCov Co sold out of Maravai LifeSciences (MRVI) in Q2 2026, closing a stake of 161,685 shares — an estimated $458K sold.

VarCov Co first reported a position in MRVI in Q1 2026 and held it in 1 quarter. The position peaked at $458K in Q1 2026. 177 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

VarCov Co reported no remaining Maravai LifeSciences position as of Q2 2026 after selling out during the quarter.
VarCov Co sold 161,685 Maravai LifeSciences shares in Q2 2026, an estimated $458K.
VarCov Co first reported a position in Maravai LifeSciences in Q1 2026 and held it in 1 quarter.
VarCov Co's Maravai LifeSciences position peaked at $458K in Q1 2026.
177 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.